JaLCDOI 10.18926/AMO/31725
フルテキストURL fulltext.pdf
著者 Tai, Chun-Hwi| Wu, Ruey-meei|
抄録 <p>Parkinson's disease (PD) is one of the main causes of neurological disability in the elderly. Levodopa is the gold standard for treating this disease, but chronic levodopa therapy is complicated by motor fluctuation and dyskinesia. The catechol-O-methyltransferase (COMT) inhibitors represent a new class of antiparkinsonian drugs. When coadministered with levodopa/decarboxylase inhibitor, 2 COMT inhibitors, tolcapone and entacapone have been shown to improve the clinical benefit of levodopa. COMT activity is genetically polymorphic, and individuals with the low activity (COMT(L/L)) genotype have a thermolabile COMT protein; studies suggest that this genotype is less common in Asians than in Caucasians. Differences in COMT activity may determine the individual response to levodopa and result in ethnic differences in PD susceptibility. Our recent study suggests that the COMTL allele can interact with the MAOB gene to increase the occurrence of PD in Taiwanese. In order to understand this new class of antiparkinsonian drugs, we review their basic properties, pharmacology, and clinical efficacy. The frequency distribution of COMT genetic polymorphisms among different populations and its implications in the etiology and drug response is also discussed.</p>
キーワード parkinson's disease catechol-O-methyltransferase catechol-O-methyltransferase inhibitors genetic polymorphism susceptibility
Amo Type Article
発行日 2002-02
出版物タイトル Acta Medica Okayama
出版者 Okayama University Medical School
開始ページ 1
終了ページ 6
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 11873938
Web of Science KeyUT 000174031300001